CCL20 在银屑病中的作用:疾病严重程度、炎症和血管健康受损的潜在生物标志物。

CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health.

机构信息

Department of Internal Medicine, New York University School of Medicine, New York, New York.

Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York; Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York.

出版信息

J Am Acad Dermatol. 2021 Apr;84(4):913-920. doi: 10.1016/j.jaad.2020.10.094. Epub 2020 Nov 28.

Abstract

BACKGROUND

Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers.

OBJECTIVE

To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis.

METHODS

In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells.

RESULTS

In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cytokines. Vascular endothelial inflammation correlated with CCL20 (r = 0.55; P < .001) and less so with IL-6 (r = 0.36; P = .04) and IL-17A (r = 0.29; P = .12). After adjustment for potential confounders, the association between CCL20 and vascular endothelial inflammation remained significant (β = 1.71; P = .02). In nested models, CCL20 added value (χ = 79.22; P < .001) to a model already incorporating the Psoriasis Area and Severity Index, Framingham risk, high-sensitivity C-reactive protein, Il-17A, and IL-6 (χ = 48.18; P < .001) in predicting vascular endothelial inflammation.

LIMITATIONS

Our study was observational and did not allow for causal inference in the relationship between CCL20 and cardiovascular risk.

CONCLUSION

We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.

摘要

背景

银屑病与心血管风险增加有关,而传统的促炎生物标志物并不能捕捉到这一点。

目的

研究银屑病患者的银屑病面积和严重程度指数(PASI)、循环促炎生物标志物与血管健康之间的关系。

方法

在银屑病患者和年龄、性别匹配的对照组中,使用 Olink Bioscience 的 Proseek 多指标心血管疾病试剂试剂盒和炎症试剂试剂盒分析了 273 种蛋白,通过直接检测肱动脉内皮细胞的转录组分析测量血管内皮炎症和健康。

结果

在银屑病中,趋化因子配体 20(CCL20)、白细胞介素(IL)6 和 IL-17A 是前 3 位循环促炎细胞因子。血管内皮炎症与 CCL20 相关(r=0.55;P<0.001),与 IL-6 相关性较小(r=0.36;P=0.04),与 IL-17A 相关性更小(r=0.29;P=0.12)。在调整了潜在混杂因素后,CCL20 与血管内皮炎症之间的关联仍然显著(β=1.71;P=0.02)。在嵌套模型中,CCL20 增加了模型的预测价值(χ²=79.22;P<0.001),该模型已经纳入了 PASI、弗雷明汉风险评分、高敏 C 反应蛋白、IL-17A 和 IL-6(χ²=48.18;P<0.001),用于预测血管内皮炎症。

局限性

我们的研究是观察性的,不能在 CCL20 与心血管风险之间的关系中进行因果推断。

结论

我们证明 CCL20 的表达与血管内皮炎症密切相关,反映了全身炎症,可能是银屑病患者血管健康受损的潜在生物标志物。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索